Shanghai Henlius Biotech Co. Ltd.

Multiple biosimilars and a generic medicine received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use at the end of July. While positive opinions d

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. JCR Adds $825m Gene Therapy Tech D

Shanghai Henlius Biotech has opened the door potentially for faster commercialization of a pair of key biosimilars in Europe, after receiving European Medicines Agency good manufacturing practice cert

As its PD-L1-targeting antibody-drug conjugate (ADC) candidate HLX43 moves into a global-first Phase II trial in China and the US, Shanghai Henlius Biotech sees in the study a launchpad to lift the ag